Ricci Vincenzo, Ronzoni Monica, Fabozzi Teresa
Oncology Department, San Raffaele Institute, 60, Olgettina St., 20132 Milan, Italy.
San Raffaele Institute, 60, Olgettina St., 20132 Milan, Italy.
Crit Rev Oncol Hematol. 2015 Dec;96(3):569-76. doi: 10.1016/j.critrevonc.2015.07.001. Epub 2015 Jul 8.
Angiogenesis is the process through which new blood vessels are formed from pre-existing vessels and is essential for the growth of all solid tumors. Vascular endothelial growth factor (VEGF) is a regulator of angiogenesis, which is crucial for tumor growth and metastasis. Its inhibition with antiangiogenic drugs is thought to improve delivery of chemotherapy through vascular normalization and disruption of tumor vasculature. Aflibercept is a recombinant fusion protein of the VEGF receptor (VEGFR)1 and VEGFR2 extracellular domains that binds to VEGF-A, VEGF-B, placental growth factor (PlGF) 1 and 2. Aflibercept has demonstrated preclinical efficacy in different tumor types and exerts its antiangiogenic effects through regression of tumor vasculature, remolding of vasculature, and inhibition of new tumor vessel growth. This review examines the effects of aflibercept on tumor vasculature and on different types of solid tumors, and explores the preclinical and clinical benefits of inclusion aflibercept into anticancer treatment strategies.
血管生成是指从已有的血管中形成新血管的过程，对所有实体瘤的生长至关重要。血管内皮生长因子（VEGF）是血管生成的调节因子，对肿瘤生长和转移至关重要。人们认为，用抗血管生成药物抑制它可通过血管正常化和破坏肿瘤脉管系统来改善化疗药物的递送。阿柏西普是一种VEGF受体（VEGFR）1和VEGFR2细胞外结构域的重组融合蛋白，可与VEGF-A、VEGF-B、胎盘生长因子（PlGF）1和2结合。阿柏西普已在不同肿瘤类型中显示出临床前疗效，并通过肿瘤脉管系统消退、脉管系统重塑和抑制新肿瘤血管生长发挥其抗血管生成作用。本综述探讨了阿柏西普对肿瘤脉管系统和不同类型实体瘤的影响，并探讨了将阿柏西普纳入抗癌治疗策略的临床前和临床益处。
